Results
|
1.
|
Beneficial effects of once-daily lixisenatide on overall and postprandial glycemic levels without significant excess of hypoglycemia in type 2 diabetes inadequately controlled on a sulfonylurea with or without metformin (GetGoal-S). MedStar authors:
Year: 2014
Citation: - Journal of Diabetes & its Complications. 28(3):386-92, 2014 May-Jun.
Institution: - MedStar Health Research Institute
Medline publication type:
- Clinical Trial, Phase III
- Journal Article
- Randomized Controlled Trial
- Research Support, Non-U.S. Gov't
All authors: - Boka G, Hanefeld M, Min KW, Miossec P, Muehlen-Bartmer I, Ratner RE, Rosenstock J, Shamanna P, Zhou T
|
|
2.
|
Pioglitazone slows progression of atherosclerosis in prediabetes independent of changes in cardiovascular risk factors. MedStar authors:
Year: 2013
Citation: - Arteriosclerosis, Thrombosis & Vascular Biology. 33(2):393-9, 2013 Feb.
Institution: - MedStar Health Research Institute
Medline publication type:
- Journal Article
- Multicenter Study
- Randomized Controlled Trial
- Research Support, Non-U.S. Gov't
- Research Support, U.S. Gov't, Non-P.H.S.
All authors: - Banerji M, Bray GA, Buchanan TA, Clement SC, DeFronzo RA, Henry RR, Hodis HN, Kitabchi AE, Mack WJ, Mudaliar S, Musi N, Ratner RE, Reaven PD, Saremi A, Schwenke DC, Stentz FB, Tripathy D
|
|
3.
|
Evaluation of in-stent restenosis in the APPROACH trial (Assessment on the Prevention of Progression by Rosiglitazone On Atherosclerosis in diabetes patients with Cardiovascular History). MedStar authors:
Year: 2012
Citation: - The International Journal of Cardiovascular Imaging. 28(3):455-65, 2012 Mar.
Institution: - MedStar Health Research Institute
Medline publication type:
- Comparative Study
- Journal Article
- Multicenter Study
- Randomized Controlled Trial
- Research Support, Non-U.S. Gov't
All authors: - APPROACH study group, Brugaletta S, Garcia-Garcia HM, Garg S, Huang C, Kolatkar NS, Kravitz BG, Miller DM, Morocutti G, Nesto RW, Ratner RE, Serruys PW
|